112 completed, 49 unknown, 39 recruiting, 28 active not recruiting. 268 Phase 3, 31 Phase 2.
Follow Lymphoma, B-Cell: new trials by email Literature Review of Lymphoma, B-Cell trials Research Report on Lymphoma, B-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Recruiting | National Cancer Institute (NCI) | 271 | 2027-07-27 | 2026-11-17 |
| A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5 Surovatamig, Rituximab, Cyclophosphamide - Large B-cell Lymphoma | Phase 3 | Not yet recruiting | AstraZeneca | 1200 | 2026-12-22 | 2026-11-02 |
| A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010) MK-1045, Zilovertamab vedotin, Rituximab - Lymphoma, Large B-Cell, Diffuse, Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Merck Sharp & Dohme LLC | 470 | 2026-12-13 | 2026-11-05 |
| A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma JS203 in combination with gemcitabine and oxaliplatin, Rituximab in combination with gemcitabine and oxaliplatin - Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 282 | 2026-10-08 | 2026-10-14 |
| Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma Orelabrutinib, ICP-248 - Relapsed/Refractory Marginal Zone Lymphoma (MZL) | Phase 3 | Not yet recruiting | Beijing InnoCare Pharma Tech Co., Ltd. | 292 | 2026-10-01 | 2026-10-27 |
| Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies IgPro20 - Secondary Immune Deficiency | Phase 3 | Recruiting | CSL Behring | 63 | 2026-09-15 | 2026-10-14 |
| International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) Inotuzumab ozogamicin (INO), Blinatumomab - B-Cell Acute Lymphoblastic Leukaemia | Phase 3 | Recruiting | Charite University, Berlin, Germany | 750 | 2026-09-01 | 2026-10-26 |
| Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19) Birelentinib, Rituximab, Cyclophosphamid - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 / Phase 3 | Not yet recruiting | Dizal Pharmaceuticals | 880 | 2026-09-01 | 2026-08-05 |
| Immunoglobulin Replacement Therapy (IgRT) Versus Antibiotic Prophylaxis (PA) in Patients Treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B Cell Acute Lymphoblastic Leukemia or a B Cell Lymphoma Immunoglobulin, antibiotic prophylaxis - Chimeric Antigen Receptor T-cell Therapy, B Cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 228 | 2026-09-01 | 2026-08-10 |
| Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL NX-5948, Pirtobrutinib - B-cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 3 | Recruiting | Nurix Therapeutics, Inc. | 620 | 2026-08-03 | 2026-08-31 |
| Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP Chidamide, Entecavir Tablets - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 3 | Recruiting | Ou Bai, MD/PHD | 200 | 2026-05-30 | 2026-03-25 |
| A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) MK-1045, Blinatumomab, Acetaminophen - B-cell Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 340 | 2026-05-18 | 2026-11-10 |
| A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL HMPL-760, HMPL-760 Placebo, R-GemOx - Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | Hutchmed | 240 | 2026-03-20 | 2026-11-10 |
| Modified DHAP Versus Standard DHAP in Relapsed/Refractory Diffused Large B-cell Lymphoma. Cisplatin (modified schedule), Cisplatin, Dexametasone - DLBCL - Diffuse Large B Cell Lymphoma | Phase 3 | Recruiting | King Edward Medical University | 74 | 2026-03-18 | 2026-08-10 |
| A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel - Large B-cell Lymphoma, Lymphoma, B-Cell | Phase 3 | Recruiting | Lyell Immunopharma, Inc. | 400 | 2026-01-12 | 2026-11-04 |
| A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia Fludarabine, Cyclophosphamide, CAR-T - B-cell Acute Lymphoblastic Leukemia | Phase 3 | Recruiting | Memorial Sloan Kettering Cancer Center | 130 | 2025-10-20 | 2026-11-12 |
| NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) Talikabtagene Autoleucel - Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL), Relapsed/Refractory Non-Hodgkin Lymphoma | Phase 2 / Phase 3 | Recruiting | Health Institutes of Turkey | 40 | 2025-09-11 | 2026-03-30 |
| Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma Xinlikang capsules, mimic capsules - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 / Phase 3 | Recruiting | Sun Yat-sen University | 80 | 2025-09-11 | 2025-11-26 |
| A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma Purinostat Mesylate for Injection, Selinexor Tablets - Recurrent and Refractory Diffuse Large B-cell Lymphoma | Phase 3 | Recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 390 | 2025-07-18 | 2025-09-19 |
| A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas Radiation (Standard), Radiation (Very low dose) - Follicular Lymphoma, Marginal Zone Lymphoma | Phase 3 | Recruiting | Memorial Sloan Kettering Cancer Center | 375 | 2025-06-09 | 2026-10-26 |
Showing 20 of 268. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (185) · Lymphoma (87) · Lymphoma, Non-Hodgkin (80) · Lymphoma, Follicular (77) · Burkitt Lymphoma (76) · Lymphoma, B-Cell, Marginal Zone (71) · Leukemia, Lymphocytic, Chronic, B-Cell (58) · Lymphoma, Mantle-Cell (54) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (51) · Lymphoma, Large-Cell, Immunoblastic (50) · Hodgkin Disease (35) · Multiple Myeloma (29) · Leukemia (28) · Leukemia, Myeloid, Chronic-Phase (27)
Hemic and Lymphatic Diseases (268) · Neoplasms by Histologic Type (267) · Immune System Diseases (266) · Immunoproliferative Disorders (265) · Lymphatic Diseases (265) · Lymphoproliferative Disorders (259) · Neoplasms (253) · Lymphoma, Non-Hodgkin (188) · Lymphoma (181) · Hematologic Diseases (81) · DNA Virus Infections (76) · Epstein-Barr Virus Infections (76) · Herpesviridae Infections (76) · Leukemia, Lymphoid (76)
Rituximab (115) · Cyclophosphamide (75) · Vincristine (65) · Doxorubicin (62) · Prednisone (56) · Etoposide (33) · Cytarabine (28) · Radiotherapy (25) · Methotrexate (22) · Dexamethasone (20) · Lenalidomide (19) · Gemcitabine (18) · Filgrastim (16) · Bendamustine Hydrochloride (14) · Prednisolone (13)
Children's Oncology Group (9) · National Cancer Institute (NCI) (9) · Hoffmann-La Roche (8) · Lymphoma Study Association (8) · Ruijin Hospital (8) · Memorial Sloan Kettering Cancer Center (6) · European Organisation for Research and Treatment of Cancer - EORTC (5) · Fred Hutchinson Cancer Center (5) · Incyte Corporation (5) · Loxo Oncology, Inc. (5) · Fondazione Italiana Linfomi - ETS (4) · Genmab (4) · German High-Grade Non-Hodgkin's Lymphoma Study Group (4) · Gilead Sciences (4) · Merck Sharp & Dohme LLC (4)
United States (126) · China (85) · France (70) · United Kingdom (65) · Italy (64) · Australia (59) · Canada (59) · Spain (55) · Belgium (54) · Germany (53) · Poland (47) · Israel (42) · South Korea (41) · Czechia (40) · Switzerland (37)
Corinne Haioun, MD (3) · Brenda Sandmaier (2) · Catherine Patte, MD (2) · David J. Straus, MD (2)
PMID 26373676, PMID 27282998, PMID 42699559, PMID 11807147, PMID 16754935, PMID 23065509, PMID 23233721, PMID 30770362, PMID 32499241, PMID 32589970, PMID 32817282, PMID 33288485, PMID 34515338, PMID 37890117, PMID 39121442, PMID 39563886, PMID 41671463, PMID 41749915, PMID 42329537, PMID 10820362, PMID 12419745, PMID 14998846, PMID 15459300, PMID 15621843, PMID 15659500, PMID 15867204, PMID 15914552, PMID 16148284, PMID 16449523, PMID 16648042, PMID 16710026, PMID 16879771, PMID 16888080, PMID 17071492, PMID 17132719, PMID 17138821, PMID 17397698, PMID 17400912, PMID 17439836, PMID 17654614, PMID 17785567, PMID 17889355, PMID 17971487, PMID 18005385, PMID 18065407, PMID 18226581, PMID 18256325, PMID 18293016, PMID 18371107, PMID 18400558
2023 (9), U10CA180886 (5), U10CA098543 (4), 2016 (3), 2017 (3), 2025 (3), U10CA032102 (3), U10CA180821 (3), 2019 (2), P01CA015396 (2), P30CA006973 (2), P30CA015083 (2), P30CA015704 (2), P30CA068485 (2), U10CA021115 (2)